What is Cognoa?
Cognoa is dedicated to transforming the landscape of child developmental health through innovative technology. Their flagship product, Canvas Dx, is the first FDA-authorized diagnostic solution designed to aid clinicians in diagnosing or ruling out autism in children aged 1.5 to 6 years within days. Leveraging advanced AI and machine learning, Cognoa addresses critical delays and inequities in autism diagnosis, offering a faster, more objective, and accessible approach. The company's commitment to a whole-child perspective positions it as a key player in the digital health sector, particularly within the specialized field of pediatric behavioral health.
How much funding has Cognoa raised?
Cognoa has raised a total of $15.4M across 2 funding rounds:
Series A
$3.8M
Private Equity
$11.6M
Series A (2016): $3.8M with participation from Morningside Group
Private Equity (2017): $11.6M led by Morningside Group
Key Investors in Cognoa
Morningside Group
Morningside Group is a notable investor with a history of backing companies in various sectors. Their involvement suggests a strategic interest in Cognoa's innovative approach to pediatric behavioral health and digital diagnostics.
What's next for Cognoa?
With the recent infusion of major strategic investment, Cognoa is poised for significant expansion and further development of its AI-driven diagnostic and therapeutic solutions. This capital injection is anticipated to fuel advancements in their technology, broaden market reach, and enhance their ability to serve a greater number of children and families facing developmental challenges. The company's focus on early detection and intervention for conditions like autism is critical, and this funding will likely support efforts to scale their operations and solidify their position as a leader in pediatric digital health. Future growth may involve expanding the diagnostic capabilities of Canvas Dx and developing new therapeutic interventions.
See full Cognoa company page
